Brian Park, PharmD

Drug Information Specialist https://www.empr.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Drugs in the Pipeline

Eplontersen Gets Orphan Drug Status for Transthyretin-Mediated Amyloidosis

Brian Park, PharmD

January 26, 2022

Eplontersen is a ligand-conjugated antisense medicine designed to reduce the production of TTR protein to treat both hereditary and nonhereditary forms of ATTR.

Drugs in the Pipeline

Risdiplam Gets Prority Review for Presymptomatic Spinal Muscular Atrophy

Brian Park, PharmD

January 25, 2022

Risdiplam is a survival motor neuron 2 splicing modifier.

News

FDA Restricts Use of 2 Monoclonal Antibody Therapies Due to Omicron Variant

Brian Park, PharmD

January 25, 2022

These monoclonal antibody treatments were found to be “highly unlikely to be active against the Omicron variant, which is circulating at a very high frequency throughout the United States.”

News

Nucala 40mg Prefilled Syringe Approved for Children With Severe Eosinophilic Asthma

Brian Park, PharmD

January 25, 2022

The FDA has approved a 40mg prefilled syringe for Nucala (mepolizumab) as add-on maintenance treatment for children with severe eosinophilic asthma.

News

FDA Clears PICO Systems for Closed Surgical Incisions to Reduce Wound Complications

Brian Park, PharmD

January 25, 2022

The clearance was based on data from 25 clinical studies which included 5560 patients.

Drugs in the Pipeline

FDA Rejects Gefapixant NDA for Chronic Cough

Brian Park, PharmD

January 24, 2022

The application includes data from the two phase 3 studies, which evaluated the efficacy and safety of gefapixant in adults with refractory or unexplained chronic cough for at least 1 year.

News

Purified Cortrophin Gel Now Available for Certain Chronic Autoimmune Disorders

Brian Park, PharmD

January 24, 2022

The product is available through a network of specialty pharmacies and distributors.

Drugs in the Pipeline

FDA Denies Approval of Long-Acting Pediatric Growth Hormone Therapy

Brian Park, PharmD

January 24, 2022

Pfizer is evaluating the FDA’s comments in the CRL and will work with the Agency to determine the appropriate steps forward.

News

Skyrizi Gets FDA Approval for Psoriatic Arthritis

Brian Park, PharmD

January 24, 2022

The approval was based on data from 2 pivotal phase 3 studies, which compared Skyrizi to placebo in adults with active PsA who had an inadequate response or were intolerant to biologic therapy and/or nonbiologic DMARDs.

Drugs in the Pipeline

Bimekizumab Meets All Endpoints in Psoriatic Arthritis Trial

Brian Park, PharmD

January 21, 2022

The phase 3 BE COMPLETE study included 400 adults with active psoriatic arthritis who were inadequate responders or intolerant to anti-TNF-α therapy.